|
1
|
Meel R, Radhakrishnan V and Bakhshi S:
Current therapy and recent advances in the management of
retinoblastoma. Indian J Med Paediatr Oncol. 33:80–88. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, Liu X, Zuo T, Liu Y and Zhang JH:
Tetramethylpyrazine reverses multidrug resistance in breast cancer
cells through regulating the expression and function of
P-glycoprotein. Med Oncol. 29:534–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang XB, Wang SS, Zhang QF, Liu M, Li HL,
Liu Y, Wang JN, Zheng F, Guo LY and Xiang JZ: Inhibition of
tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug
resistant human hepatocellular carcinoma cells. Oncol Rep.
23:211–215. 2010.PubMed/NCBI
|
|
4
|
Yin J, Yu C, Yang Z, He JL, Chen WJ, Liu
HZ, Li WM, Liu HT and Wang YX: Tetramethylpyrazine inhibits
migration of SKOV3 human ovarian carcinoma cells and decreases the
expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling
pathways. Oncol Rep. 26:671–679. 2011.PubMed/NCBI
|
|
5
|
Cao J, Miao Q, Miao S, Bi L, Zhang S, Yang
Q, Zhou X, Zhang M, Xie Y, Zhang J and Wang S: Tetramethylpyrazine
(TMP) exerts antitumor effects by inducing apoptosis and autophagy
in hepatocellular carcinoma. Int Immunopharmacol. 26:212–220. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang XJ, Xu YH, Yang GC, Chen HX and Zhang
P: Tetramethylpyrazine inhibits the proliferation of acute
lymphocytic leukemia cell lines via decrease in GSK-3β. Oncol Rep.
33:2368–2374. 2015.PubMed/NCBI
|
|
7
|
Jiang Y, Liu C, Chen W, Wang H, Wang C and
Lin N: Tetramethylpyrazine enhances vascularization and prevents
osteonecrosis in steroid-treated rats. Biomed Res Int.
2015:3158502015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang L, Deng M and Zhou S:
Tetramethylpyrazine inhibits hypoxia-induced pulmonary vascular
leakage in rats via the ROS-HIF-VEGF pathway. Pharmacology.
87:265–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cai X, Chen Z, Pan X, Xia L, Chen P, Yang
Y, Hu H, Zhang J, Li K, Ge J, et al: Inhibition of angiogenesis,
fibrosis and thrombosis by tetramethylpyrazine: Mechanisms
contributing to the SDF-1/CXCR4 axis. PLoS One. 9:e881762014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
You JM, Zhang ZG, Liu C and Ji YX:
Ischemic stroke and the regulation of syndrome of traditional
Chinese medicine compound efficacy TMP combined. Chin Archives
Tradit Chin Med. 28:2666–2668. 2010.
|
|
11
|
Tang ZY, Wang SL and Lin Y: Progress in
protective effects of tetramethylpyrazine on diabetes complications
in nervous system and possible mechanisms. Chin J Pharmacol
Toxicol. 25:114–118. 2011.
|
|
12
|
Chen Y and Liu M: Systemic evaluation of
security of ligustrazine for treatment of cerebral infarction. Chin
J Clin Rehab. 8:1299–1301. 2004.
|
|
13
|
Yang XG and Jiang C: Ligustrazine as a
salvage agent for patients with relapsed or refractory
non-Hodgkin's lymphoma. Chin Med J (Engl). 123:3206–3211.
2010.PubMed/NCBI
|
|
14
|
Chen Z, Pan X, Georgakilas AG, Chen P, Hu
H, Yang Y, Tian S, Xia L, Zhang J, Cai X, et al:
Tetramethylpyrazine (TMP) protects cerebral neurocytes and inhibits
glioma by down regulating chemokine receptor CXCR4 expression.
Cancer Lett. 336:281–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Furusato B, Mohamed A, Uhlén M and Rhim
JS: CXCR4 and cancer. Pathol Int. 60:497–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X and Chen X: Study on the effects of
tetramethylpyrazine on tumor cells: Survey and prospects. Zhongguo
Zhong Yao Za Zhi. 28:295–298. 2003.(In Chinese). PubMed/NCBI
|
|
17
|
Muller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu K, Chen Z, Pan X, Yang Y, Tian S, Zhang
J, Ge J, Ambati B and Zhuang J: Tetramethylpyrazine-mediated
suppression of C6 gliomas involves inhibition of chemokine receptor
CXCR4 expression. Oncol Rep. 28:955–960. 2012.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schulte A, Günther HS, Phillips HS,
Kemming D, Martens T, Kharbanda S, Soriano RH, Modrusan Z, Zapf S,
Westphal M and Lamszus K: A distinct subset of glioma cell lines
with stem cell-like properties reflects the transcriptional
phenotype of glioblastomas and overexpresses CXCR4 as therapeutic
target. Glia. 59:590–602. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Darash-Yahana M, Pikarsky E, Abramovitch
R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E
and Peled A: Role of high expression levels of CXCR4 in tumor
growth, vascularization, and metastasis. FASEB J. 18:1240–1242.
2004.PubMed/NCBI
|
|
22
|
Mo W, Chen J, Patel A, Zhang L, Chau V, Li
Y, Cho W, Lim K, Xu J, Lazar AJ, et al: CXCR4/CXCL12 mediate
autocrine cell-cycle progression in NF1-associated malignant
peripheral nerve sheath tumors. Cell. 152:1077–1090. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang P, Wang G, Huo H, Li Q, Zhao Y and
Liu Y: SDF-1/CXCR4 signaling up-regulates survivin to regulate
human sacral chondrosarcoma cell cycle and epithelial-mesenchymal
transition via ERK and PI3K/AKT pathway. Med Oncol. 32:3772015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu T, Wu Y, Huang Y, Yan C, Liu Y, Wang Z,
Wang X, Wen Y, Wang C and Li L: RNAi targeting CXCR4 inhibits tumor
growth through inducing cell cycle arrest and apoptosis. Mol Ther.
20:398–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ji AJ, Liu SL, Ju WZ and Huang XE:
Anti-proliferation effects and molecular mechanisms of action of
tetramethypyrazine on human SGC-7901 gastric carcinoma cells. Asian
Pac J Cancer Prev. 15:3581–3586. 2014. View Article : Google Scholar : PubMed/NCBI
|
